A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2018

At a glance

  • Drugs Elagolix (Primary) ; Estradiol/norethisterone
  • Indications Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ELARIS UF-II
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Aug 2018 According to an AbbVie media release, Data from the pivotal Phase 3 (ELARIS UF-I and ELARIS UF-II) studies will be presented at a medical conference later this year.
    • 26 Apr 2018 Planned End Date changed from 15 Jan 2019 to 16 Jan 2019.
    • 13 Mar 2018 Results published in the AbbVie Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top